Loading...
ACB logo

Aurora Cannabis Inc.NasdaqCM:ACB Stock Report

Market Cap US$260.1m
Share Price
US$4.49
n/a
1Y6.9%
7D-4.3%
Portfolio Value
View

Aurora Cannabis Inc.

NasdaqCM:ACB Stock Report

Market Cap: US$260.1m

Aurora Cannabis (ACB) Stock Overview

Engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. More details

ACB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ACB Community Fair Values

Create Narrative

See what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.

Aurora Cannabis Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aurora Cannabis
Historical stock prices
Current Share PriceCA$4.49
52 Week HighCA$6.91
52 Week LowCA$3.42
Beta1.22
1 Month Change-2.39%
3 Month Change-24.66%
1 Year Change6.90%
3 Year Change-51.33%
5 Year Change-95.28%
Change since IPO-88.05%

Recent News & Updates

Aurora Cannabis: Upgrading On High-Margin Medical Cannabis Sales Growth - Buy

Nov 06

Recent updates

Aurora Cannabis: Upgrading On High-Margin Medical Cannabis Sales Growth - Buy

Nov 06

Aurora Cannabis: This Phoenix Has Risen From The Ashes (Strong Buy Initiation)

Feb 22

Aurora Cannabis: Revving Up To Profitability

Aug 08

Aurora launches new cannabis products for adult and medical-use

Oct 17

Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes

Oct 07

Aurora Cannabis Q4 2022 Earnings Preview

Sep 19

Aurora Cannabis: Don't Let Your Money Go Up In Smoke

Aug 25

Why Did Aurora Cannabis Stock Crash In May; Can It Recover?

Jun 13

Recent Developments Do Not Change Our Stance On Aurora Cannabis

May 13

Aurora Cannabis: A Train Wreck Desperate For Help

May 05

Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way

Feb 17

Aurora Cannabis Vs. HEXO: Which Is The Better Cannabis Stock?

Dec 17

Tilray Vs. Aurora Cannabis: How To Compare These Cannabis Stocks

Oct 11

Aurora Cannabis: Investors Should Have No Confidence In This Company

Sep 28

Shareholder Returns

ACBUS PharmaceuticalsUS Market
7D-4.3%0.4%0.6%
1Y6.9%27.6%17.0%

Return vs Industry: ACB underperformed the US Pharmaceuticals industry which returned 27.6% over the past year.

Return vs Market: ACB underperformed the US Market which returned 17% over the past year.

Price Volatility

Is ACB's price volatile compared to industry and market?
ACB volatility
ACB Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement6.5%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market2.9%

Stable Share Price: ACB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ACB's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20131,073Miguel Martinwww.auroramj.com

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers pharmaceutical-grade cannabis products; medical and consumer cannabis products; and engages in the propagation of vegetables and floral plants.

Aurora Cannabis Inc. Fundamentals Summary

How do Aurora Cannabis's earnings and revenue compare to its market cap?
ACB fundamental statistics
Market capUS$260.09m
Earnings (TTM)-US$41.74m
Revenue (TTM)US$268.57m
1.0x
P/S Ratio
-6.2x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACB income statement (TTM)
RevenueCA$367.13m
Cost of RevenueCA$204.38m
Gross ProfitCA$162.74m
Other ExpensesCA$219.80m
Earnings-CA$57.06m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.01
Gross Margin44.33%
Net Profit Margin-15.54%
Debt/Equity Ratio10.5%

How did ACB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/29 14:36
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aurora Cannabis Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Frederico Yokota Choucair GomesATB Capital Markets
Tamy ChenBMO Capital Markets Equity Research
Etienne RicardBMO Capital Markets Equity Research